Inovio Pharmaceuticals (INO)
(Real Time Quote from BATS)
$10.56 USD
+0.44 (4.30%)
Updated Apr 26, 2024 03:28 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
INO 10.56 +0.44(4.30%)
Will INO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INO
Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates
INO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know
Inovio (INO) Moves 17.4% Higher: Will This Strength Last?
How Much Upside is Left in Inovio (INO)? Wall Street Analysts Think 223.72%
Other News for INO
Inovio Pharmaceuticals: Neutral On INO-3107 Amidst Stock Dilution And High Valuation
Inovio Pharmaceuticals: The Dilution Continues
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors